nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A new approach to refractory gastrointestinal stromal tumours with diverse acquired mutations
|
Nishida, Toshirou |
|
|
21 |
7 |
p. 864-865 |
artikel |
2 |
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
|
Tiu, Crescens |
|
|
21 |
7 |
p. 889-891 |
artikel |
3 |
2020 ASCO Virtual Annual Meeting
|
Collingridge, David |
|
|
21 |
7 |
p. 885-886 |
artikel |
4 |
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
|
Heinrich, Michael C |
|
|
21 |
7 |
p. 935-946 |
artikel |
5 |
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
|
Konstantinopoulos, Panagiotis A |
|
|
21 |
7 |
p. 957-968 |
artikel |
6 |
Cancer and the microbiome
|
Gunjur, Ashray |
|
|
21 |
7 |
p. 888 |
artikel |
7 |
Cancer registration in China and its role in cancer prevention and control
|
Wei, Wenqiang |
|
|
21 |
7 |
p. e342-e349 |
artikel |
8 |
Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study
|
Tian, Jianbo |
|
|
21 |
7 |
p. 893-903 |
artikel |
9 |
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
|
Yang, Kunyu |
|
|
21 |
7 |
p. 904-913 |
artikel |
10 |
Correction to Lancet Oncol 2020; 21: 271–82
|
|
|
|
21 |
7 |
p. e341 |
artikel |
11 |
Correction to Lancet Oncol 2020; 21: 851–60
|
|
|
|
21 |
7 |
p. e341 |
artikel |
12 |
Correction to Lancet Oncol 2020; 21: 923–34
|
|
|
|
21 |
7 |
p. e341 |
artikel |
13 |
Correction to Lancet Oncol 2020; 21: 261–70
|
|
|
|
21 |
7 |
p. e341 |
artikel |
14 |
Correction to Lancet Oncol 2020; 21: 808–20
|
|
|
|
21 |
7 |
p. e341 |
artikel |
15 |
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
|
Garassino, Marina Chiara |
|
|
21 |
7 |
p. 914-922 |
artikel |
16 |
Developing anti-CD19 antibody-based combinations in lymphoma
|
Kuruvilla, John |
|
|
21 |
7 |
p. 870-872 |
artikel |
17 |
Digital tools for sharing genetic information with family members
|
Phillips, Amicia |
|
|
21 |
7 |
p. 891-892 |
artikel |
18 |
ESGO–SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers
|
Sessa, Cristiana |
|
|
21 |
7 |
p. e360-e368 |
artikel |
19 |
Has dose-dense chemotherapy met an ICONic end?
|
Hinchcliff, Emily M |
|
|
21 |
7 |
p. 869-870 |
artikel |
20 |
Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma?
|
Ferrer-Fàbrega, Joana |
|
|
21 |
7 |
p. 867-869 |
artikel |
21 |
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial
|
Mazzaferro, Vincenzo |
|
|
21 |
7 |
p. 947-956 |
artikel |
22 |
Lockdown poses new challenges for cancer care in India
|
Sharma, Dinesh C |
|
|
21 |
7 |
p. 884 |
artikel |
23 |
Moving gastrointestinal stromal tumours towards truly personalised precision therapy
|
Nguyen, Vi |
|
|
21 |
7 |
p. 865-867 |
artikel |
24 |
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial
|
Hui, David |
|
|
21 |
7 |
p. 989-998 |
artikel |
25 |
New advances in prostate cancer screening and monitoring
|
Gourd, Elizabeth |
|
|
21 |
7 |
p. 887 |
artikel |
26 |
New approaches to cancer care in a COVID-19 world
|
Butler, John |
|
|
21 |
7 |
p. e339-e340 |
artikel |
27 |
Opportunities to improve cancer control and progress towards universal health coverage in Commonwealth nations
|
Ilbawi, André |
|
|
21 |
7 |
p. 876-879 |
artikel |
28 |
Optimal goal of management of delirium in end-of-life cancer care
|
Akechi, Tatsuo |
|
|
21 |
7 |
p. 872-873 |
artikel |
29 |
Poor clinical outcomes for patients with cancer during the COVID-19 pandemic
|
Tang, Liang V |
|
|
21 |
7 |
p. 862-864 |
artikel |
30 |
Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer
|
Ramella, Sara |
|
|
21 |
7 |
p. 873-875 |
artikel |
31 |
Racism, discrimination, and the practice of oncology
|
The Lancet Oncology, |
|
|
21 |
7 |
p. 861 |
artikel |
32 |
Radiation-induced angiosarcoma in a patient with breast cancer
|
Malekpour, Mahdi |
|
|
21 |
7 |
p. e369 |
artikel |
33 |
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus
|
Mehanna, Hisham |
|
|
21 |
7 |
p. e350-e359 |
artikel |
34 |
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
|
Blay, Jean-Yves |
|
|
21 |
7 |
p. 923-934 |
artikel |
35 |
Screening of gastrointestinal cancers during COVID-19: a new emergency
|
Maida, Marcello |
|
|
21 |
7 |
p. e338 |
artikel |
36 |
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
|
Salles, Gilles |
|
|
21 |
7 |
p. 978-988 |
artikel |
37 |
The Commonwealth: an anachronism or a relevant organisation for the future?
|
Collingridge, David |
|
|
21 |
7 |
p. 875-876 |
artikel |
38 |
The role of faith organisations in cancer control and patient care
|
Newcome, James |
|
|
21 |
7 |
p. 882-883 |
artikel |
39 |
The role of the Commonwealth in the wider cancer control agenda
|
Lodge, Mark |
|
|
21 |
7 |
p. 879-881 |
artikel |
40 |
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
|
Blagden, Sarah P |
|
|
21 |
7 |
p. 969-977 |
artikel |